222 related articles for article (PubMed ID: 15507584)
21. Promotion of prescription drugs to consumers.
Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
[TBL] [Abstract][Full Text] [Related]
22. Abbreviated hormone replacement therapy trial answers some questions, raises new ones. The Women's Health Initiative is no longer testing the most widely prescribed estrogen and progestin combination--but the study's job is far from over.
Harv Womens Health Watch; 2002 Oct; 10(2):2-4. PubMed ID: 12393317
[No Abstract] [Full Text] [Related]
23. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
[TBL] [Abstract][Full Text] [Related]
24. Impact of WHI conclusions and ACOG guidelines on clinical practice.
Gass M
Int J Fertil Womens Med; 2003; 48(3):106-10; discussion 137-8. PubMed ID: 12839140
[TBL] [Abstract][Full Text] [Related]
25. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
[TBL] [Abstract][Full Text] [Related]
26. Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles.
Fugh-Berman A; McDonald CP; Bell AM; Bethards EC; Scialli AR
PLoS Med; 2011 Mar; 8(3):e1000425. PubMed ID: 21423581
[TBL] [Abstract][Full Text] [Related]
27. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?
Machens K; Schmidt-Gollwitzer K
Hum Reprod; 2003 Oct; 18(10):1992-9. PubMed ID: 14507812
[TBL] [Abstract][Full Text] [Related]
28. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
29. Patients' and clinicians' attitudes after the Women's Health Initiative study.
Blümel JE; Castelo-Branco C; Chedraui PA; Binfa L; Dowlani B; Gómez MS; Sarrá S
Menopause; 2004; 11(1):57-61. PubMed ID: 14716183
[TBL] [Abstract][Full Text] [Related]
30. WHI clinical trial revisit: imprecise scientific methodology disqualifies the study's outcomes.
Ostrzenski A; Ostrzenska KM
Am J Obstet Gynecol; 2005 Nov; 193(5):1599-604; discussion 1605-6. PubMed ID: 16260198
[TBL] [Abstract][Full Text] [Related]
31. Women's health. More questions about hormone replacement.
Couzin J; Enserink M
Science; 2002 Nov; 298(5595):942. PubMed ID: 12411676
[No Abstract] [Full Text] [Related]
32. Estrogen plus progestin and colorectal cancer in postmenopausal women.
Chlebowski RT; Wactawski-Wende J; Ritenbaugh C; Hubbell FA; Ascensao J; Rodabough RJ; Rosenberg CA; Taylor VM; Harris R; Chen C; Adams-Campbell LL; White E;
N Engl J Med; 2004 Mar; 350(10):991-1004. PubMed ID: 14999111
[TBL] [Abstract][Full Text] [Related]
33. A clinician's review of the WHI-related literature.
Speroff L
Int J Fertil Womens Med; 2004; 49(6):252-67. PubMed ID: 15751264
[TBL] [Abstract][Full Text] [Related]
34. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
36. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies.
Shapiro S
Climacteric; 2006 Dec; 9(6):416-20. PubMed ID: 17085373
[TBL] [Abstract][Full Text] [Related]
37. Effects of combination estrogen plus progestin hormone treatment on cognition and affect.
Resnick SM; Maki PM; Rapp SR; Espeland MA; Brunner R; Coker LH; Granek IA; Hogan P; Ockene JK; Shumaker SA;
J Clin Endocrinol Metab; 2006 May; 91(5):1802-10. PubMed ID: 16522699
[TBL] [Abstract][Full Text] [Related]
38. [Postmenopausal hormone therapy after WHI and HERS].
Birkhäuser M; de Geyter C; Keller PJ; Luzuy F
Gynakol Geburtshilfliche Rundsch; 2004 Oct; 44(4):244-8. PubMed ID: 15459524
[No Abstract] [Full Text] [Related]
39. The WHI ten year's later: an epidemiologist's view.
Lacey JV
J Steroid Biochem Mol Biol; 2014 Jul; 142():12-5. PubMed ID: 24029430
[TBL] [Abstract][Full Text] [Related]
40. Hormone use and patient concerns after the findings of the Women's Health Initiative.
Rolnick SJ; Kopher RA; DeFor TA; Kelley ME
Menopause; 2005; 12(4):399-404. PubMed ID: 16037754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
